8-K: Seer Reports Q2 2026 Results, Revenue Down 23%

Seer, Inc. announced second quarter 2026 financial results, reporting $3.1 million in revenue, a 23% decrease year-over-year, and a net loss of $16.9 million, while reaffirming full-year revenue guidance.

Summary

• Seer, Inc. reported $3.1 million in revenue for the second quarter of 2026, a 23% decrease from $4.1 million in the same period last year.
• The company experienced a net loss of $16.9 million for Q2 2026, an improvement from a net loss of $19.4 million in Q2 2025.
• Operating expenses decreased by 19% to $18.3 million in Q2 2026 from $22.6 million in Q2 2025, largely due to reduced employee compensation.
• Seer reaffirmed its full-year 2026 revenue guidance to be in the range of $16 million to $18 million.
• The company ended the quarter with $209.5 million in cash, cash equivalents, and investments.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to declining revenue and a significant net loss, despite efforts to control operating expenses and a reaffirmation of guidance.

Positives

• Operating expenses decreased by 19% to $18.3 million in Q2 2026, driven by lower employee compensation, including stock-based compensation.
• Net loss improved to $16.9 million in Q2 2026 from $19.4 million in Q2 2025.
• The company ended the quarter with a strong cash position of $209.5 million.
• Seer is actively protecting its intellectual property, with the U.S. International Trade Commission opening an investigation into Nanomics Biotechnology Co., Ltd.
• An independent study published in Nature Genetics leveraged Seer's Proteograph technology.

Negatives

• Revenue for the second quarter of 2026 was $3.1 million, a 23% decrease compared to $4.1 million in the prior year period.
• The decrease in revenue is attributed to lower product and service revenue due to macroeconomic headwinds and extended sales cycles.
• Product revenue decreased to $2.3 million in Q2 2026 from $2.7 million in Q2 2025.
• Service revenue decreased to $0.7 million in Q2 2026 from $0.8 million in Q2 2025.
• The company reported a net loss of $16.9 million for the quarter.

Risks

• Continuing macroeconomic headwinds impacting academic and government funding.
• Continued elongation of sales cycles in some commercial accounts due to extended customer evaluations.
• Potential risks associated with enforcing intellectual property rights.
• The company's ability to convert scientific leadership into revenue.

Future Outlook

Seer continues to expect full year 2026 revenue to be in the range of $16 million to $18 million, representing growth of 3% at the midpoint over full year 2025.

Management Comments

• "Im proud that our technology is enabling the scientific community to do impactful work previously not possible. An important highlight this quarter was the presentation at the ASMS from our customers on how AI-driven proteomics can impact early detection of cancer," said Omid Farokhzad, Chair and Chief Executive Officer.
• "During the quarter, we strengthened our commercial team, positioning Seer to better convert scientific leadership into revenue, and we took action to protect our core intellectual property on two continents."

Industry Context

StockSavvy.ai notes that the decline in revenue for Seer, Inc. reflects broader macroeconomic challenges impacting research funding and extended sales cycles, which are common themes across the biotechnology and life sciences sectors currently.

Legal Proceedings

• Initiated enforcement of intellectual property rights against Nanomics Biotechnology Co., Ltd., with the U.S. International Trade Commission opening an investigation into Nanomics' importation of products believed to infringe Seer's patents.

Stakeholder Impact

• Shareholders may be concerned by the year-over-year revenue decline, although the net loss reduction and reaffirmed guidance may provide some reassurance.
• Employees may face uncertainty due to the revenue decline, though the reduction in operating expenses and focus on commercial team strengthening could indicate a strategic shift.
• Customers may experience longer evaluation periods, impacting their purchasing decisions.

Next Steps

• Continue to strengthen the commercial team to improve revenue conversion.
• Continue to protect core intellectual property on an ongoing basis.
• Monitor and adapt to macroeconomic headwinds and sales cycle elongations.

Key Dates

Recommendation

The company shows a significant year-over-year revenue decline, which is a negative indicator. However, the reduction in operating expenses, improved net loss, strong cash position, and reaffirmed full-year guidance suggest a potential for stabilization. The ongoing intellectual property enforcement is also a positive development. Given these mixed signals, a 'hold' recommendation is appropriate pending further evidence of revenue recovery and successful commercialization.

Keywords

proteomics, mass spectrometry, nanoparticles, cancer screening, intellectual property, revenue, net loss, financial results